Anh phê duyệt 'tên lửa sinh học' trị ung thư buồng trứng khó chữa
Anh đưa mirvetuximab soravtansine (tên thương mại Elahere), loại thuốc được ví như "tên lửa sinh học" điều trị ung thư buồng trứng kháng thuốc, vào danh mục chi trả từ ngày 4/6.
The UK has approved mirvetuximab soravtansine, commercially known as Elahere, for inclusion in its reimbursement list, effective June 4th. This drug, described as a "biological missile," is designed to treat a specific type of ovarian cancer that has become resistant to other treatments. Its inclusion means eligible patients in the UK will now have access to this targeted therapy through the national health system.
This approval offers a new, targeted treatment option for patients with difficult-to-treat relapsed ovarian cancer, potentially improving outcomes for those who have exhausted other therapeutic avenues.
📌 Kaynak
Bu özet VnExpress (VN) kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →